Glenmark Pharmaceuticals Inc., USA is recalling 102,944 units of Carvedilol (generic Coreg) tablets in several strengths: 3.125 mg, 6.25 mg, 12.5 mg, and 25 mg. This recall was initiated due to manufacturing deviations that resulted in the presence of an impurity called 'N-Nitroso Carvedilol I' at levels exceeding the recommended intake limits. These products were distributed nationwide in the United States and were manufactured by Glenmark Pharmaceuticals Ltd. in India for Glenmark Pharmaceuticals Inc., USA.
The impurity found, N-Nitroso Carvedilol I, belongs to a class of substances called nitrosamines, which are classified as probable human carcinogens. Long-term exposure to these impurities above acceptable levels may increase the risk of cancer.
You have 2 options:
Distributed in 100-count and 500-count bottles.
Distributed in 100-count and 500-count bottles.
Distributed in 500-count bottles.
Distributed in 500-count bottles.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES ยท Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.